Transanal Excision of Locally Advanced Rectal Cancers Downstaged Using Neoadjuvant Chemoradiotherapy1
Authors:
- Robert A ZloteckiRZRobert A Zlotecki
- William M MendenhallWMWilliam M Mendenhall
- Robert W MarshRMRobert W Marsh
- Nicolas J. VautheyNVNicolas J. Vauthey
- Edward M CopelandECEdward M Copeland
- 1 May 2002
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 194 (5) , 584-590
Abstract
Our institution has previously demonstrated a survival advantage conferred by preoperative neoadjuvant therapy for locally advanced rectal cancers. We now report our results using transanal excision as definitive surgical therapy in a selected group of patients who experienced significant downstaging of T3 rectal cancers after neoadjuvant therapy. Seventy-four patients diagnosed with locally advanced (T3) rectal cancers were treated with neoadjuvant chemoradiotherapy. After neoadjuvant therapy, 11 (14.9%) patients who had significant downstaging of their tumors were selected to undergo transanal excision of their residual rectal cancers. Intraoperative cryostat evaluation was used to confirm negative margin status, and all patients were subsequently followed with routine endoscopy, transrectal ultrasonography, and digital rectal examinations. Tumors were located between 1 cm and 7 cm from the anal verge (mean 4.3 +/- 0.6 cm), and were located in lateral, anterior, and posterior positions. Mean followup was 55.2 +/- 8.9 months (median 47.9 months). Imaging studies using CT, MRI, transrectal ultrasonography, or combination demonstrated suspicious lymph nodes in three patients. After neoadjuvant therapy, these lymph nodes were no longer demonstrated in two patients. There were no local recurrences, nodal metastases, or operative mortalities. One patient (9%) developed distant metastases (pulmonary nodules), and remains alive 30 months after transanal excision. One patient (9%) experienced sphincter laxity, which was successfully repaired, and is now asymptomatic. One patient (9%) developed postoperative urgency that resolved spontaneously. In patients who have initial bulky (T3) lesions, and experience significant downstaging after neoadjuvant chemoradiotherapy, transanal excision appears to be a safe and effective treatment, preserving sphincter function and avoiding laparotomy.Keywords
This publication has 17 references indexed in Scilit:
- Role of local excision in the treatment of rectal cancerSeminars in Surgical Oncology, 2000
- Preoperative Radiotherapy for Resectable Rectal CancerJAMA, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Low rectal cancerDiseases of the Colon & Rectum, 1998
- Outcome After Proctectomy for Rectal Cancer in Department of Veterans Affairs HospitalsAnnals of Surgery, 1998
- Improved Survival with Preoperative Radiotherapy in Resectable Rectal CancerNew England Journal of Medicine, 1997
- Radiotherapy in addition to radical surgery in rectal cancer: Evidence for a dose-response effect favoring preoperative treatmentInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- Radical and local excisional methods of sphincter-sparing surgery after high-dose radiation for cancer of the distal 3 cm of the rectumAnnals of Surgical Oncology, 1995
- Preoperative infusional chemoradiation and surgery with or without and electron beam intraoperative boost for advanced primary rectal cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- Does Preoperative Radiation Therapy Enhance the Probability of Local Control and Survival in High-risk Distal Rectal Cancer?Annals of Surgery, 1992